echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Sarepta's treatment of DMD antisense RNA drug Exondys 51 (eteplirsen) 3 trials yield positive results

    Sarepta's treatment of DMD antisense RNA drug Exondys 51 (eteplirsen) 3 trials yield positive results

    • Last Update: 2020-06-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, a newly published study showed that Sarepta Therapeuticscompany(http://treats Duchenne's muscular dystrophy (DMD) antonymic rnadrug(http://Exo
    ndirsen, all of which achieved positive decline in lung function in threetrial(http://of the post-validation studyExo
    ndys 51 is the first innovative treatment approved by theFDA(http://for the treatment of specific DMD patients   About Exo
    ndys 51
    Exo
    ndys 51 is a sarepta-developed phosphamide dipolytosis oligonucleotide, targeted to the shear process of the anti-amyotrophic protein mRNA precursor, designed to introduce exon 51 jumps (exon 51 skipping) to produce short but functional antimuscular hymne protein According to statistics, about 13% of DMD patients carry genetic mutations suitable for exogenous 51 jump therapy   Previous lying results have shown that Exo
    ndys 51 reached several biological endpoints in clinical trials, including the proper completion of exon jumps at RNA production levels, the expression of antimyosphin, and increased muscle strength   In the three post-market studies, Exo
    ndys 51 can delay the decline of their lung function, regardless of the stage at which the patient develops
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.